No title
INTRODUCTION: Amyloid-positron emission tomography (PET) is pivotal to Alzheimer's management, with the Centiloid standardizing measurements across tracers. AMYPAD trials (Diagnostic and Patient Management Study [DPMS] and Prognostic and Natural History Study [PNHS]) aimed to validate robust quantification in clinical settings. We report our comprehensive approach to amyloid-PET implementation, co
